Showing results (21-30 of 131) with videos related to

Sort By:
Pageof 14
Antimicrobial Agents and Chemotherapy|July 1, 1995
Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot modelS L Kang, M J Rybak
Antimicrobial Agents and Chemotherapy|March 1, 1993
Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calciumK C Lamp, M J Rybak
The Journal of Antimicrobial Chemotherapy|May 1, 1997
In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureusS L Kang, M J Rybak
Pharmacotherapy|September 1, 1996
Vancomycin-resistant enterococciS M Palmer, M J Rybak
Drug Intelligence & Clinical Pharmacy|November 1, 1986
Hematological effects associated with beta-lactam useL M Babiak, M J Rybak
Antimicrobial Agents and Chemotherapy|September 16, 1998
Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methodsJ R Aeschlimann, M J Rybak
Pharmacotherapy|June 10, 1998
The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobialsL D Dresser, M J Rybak
Pharmacotherapy|October 8, 1999
Pharmacologic and bacteriologic properties of SCH-27899 (Ziracin), an investigational antibiotic from the everninomicin familyD R Foster, M J Rybak
The Journal of Antimicrobial Chemotherapy|April 1, 1997
An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clotsS M Palmer, M J Rybak
Journal of Clinical Pharmacology|May 29, 1998
The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertensionB E Ilson, D E Martin, S C Boike, et al.
Pageof 14